Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) EPS (Basic): 2020-2024

Historic EPS (Basic) for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to -$3.07.

  • Tarsus Pharmaceuticals' EPS (Basic) rose 50.82% to -$0.30 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.01, marking a year-over-year increase of 46.68%. This contributed to the annual value of -$3.07 for FY2024, which is 33.55% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its EPS (Basic) stood at -$3.07 for FY2024, which was up 33.55% from -$4.62 recorded in FY2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' EPS (Basic) peaked at -$0.67 during FY2021, and registered a low of -$4.62 during FY2023.
  • Moreover, its 3-year median value for EPS (Basic) was -$3.07 (2024), whereas its average is -$3.40.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 84.49% in 2021, then tumbled by 276.12% in 2022.
  • Tarsus Pharmaceuticals' EPS (Basic) (Yearly) stood at -$4.32 in 2020, then spiked by 84.49% to -$0.67 in 2021, then tumbled by 276.12% to -$2.52 in 2022, then slumped by 83.33% to -$4.62 in 2023, then skyrocketed by 33.55% to -$3.07 in 2024.